Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q3 2015 · 10-Q
Revenue$28.01M$28.01M+235.5% vs Q3 2014 Net Income$105.58M$105.58MN/M vs Q3 2014 EPS Diluted$1.78$1.78N/M vs Q3 2014 Operating Income-$20,496,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$733,000N/M Margins · derivedOperating margin-73.2%+188.8 pt vs Q3 2014
Net margin377.0%+592.4 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 6, 2015 · 37 d after period end